Literature DB >> 12023386

Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints.

Yoshihiro Matsumoto1, Kazuhiro Tanaka, Go Hirata, Masuo Hanada, Shuichi Matsuda, Toshihide Shuto, Yukihide Iwamoto.   

Abstract

Vascular endothelial growth factor (VEGF) plays a crucial role in the pathogenesis of inflammatory joint disease, including angiogenesis and synovitis. Rheumatoid arthritis is a chronic inflammatory disease characterized by progressive synovitis and subsequent bone destruction mediated by osteoclasts (OCs). In this study, we investigate the effects of VEGF on OC precursor cells (pOCs) using Raw cells and adjuvant-induced arthritis in rats. OCs and pOCs in the arthritic joints express VEGF and VEGF receptor type I (Flt-1). Raw cells also express Flt-1, and VEGF treatment stimulated chemotaxis, cell proliferation, the association of Flt-1 with focal adhesion kinase (FAK), and the tyrosine phosphorylation of FAK in Raw cells. The tyrosine phosphorylation of FAK was also observed in pOCs in the arthritic joints of adjuvant-induced arthritis. Adenovirus-mediated expression of FAK-related nonkinase in Raw cells inhibited the effects of VEGF in a dominant negative manner. Furthermore, intra-articular injection of the FAK-related nonkinase virus suppressed the recruitment of pOCs and bone destruction. Our results suggest the possible involvement of the VEGF-Flt-1-FAK pathway in inflammatory disease-induced joint destruction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023386     DOI: 10.4049/jimmunol.168.11.5824

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism.

Authors:  Qian Zhang; Ruolin Guo; Yan Lu; Lan Zhao; Quan Zhou; Edward M Schwarz; Jing Huang; Di Chen; Zheng-Gen Jin; Brendan F Boyce; Lianping Xing
Journal:  J Biol Chem       Date:  2008-03-20       Impact factor: 5.157

Review 3.  Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.

Authors:  John L Hamilton; Masashi Nagao; Brett R Levine; Di Chen; Bjorn R Olsen; Hee-Jeong Im
Journal:  J Bone Miner Res       Date:  2016-04-08       Impact factor: 6.741

4.  Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Authors:  Khalid A Mohamedali; Zhi Gang Li; Michael W Starbuck; Xinhai Wan; Jun Yang; Sehoon Kim; Wendy Zhang; Michael G Rosenblum; Nora M Navone
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

Review 5.  Terminal differentiation is not a major determinant for the success of stem cell therapy - cross-talk between muscle-derived stem cells and host cells.

Authors:  Burhan Gharaibeh; Mitra Lavasani; James H Cummins; Johnny Huard
Journal:  Stem Cell Res Ther       Date:  2011-07-08       Impact factor: 6.832

6.  Arsenite-mediated promotion of anchorage-independent growth of HaCaT cells through placental growth factor.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Shoko Ohnuma; Nobutaka Ohgami; Hisao Naito; Hossain U Shekhar; Yasuhiro Omata; Masashi Kato
Journal:  J Invest Dermatol       Date:  2014-12-10       Impact factor: 8.551

7.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

8.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.

Authors:  Yoshihiro Matsumoto; Yuko Okada; Jun-Ichi Fukushi; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Mihoko Koga; Shuichi Matsuda; Katsumi Harimaya; Akio Sakamoto; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2010-11-09       Impact factor: 2.359

9.  High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.

Authors:  Laura M Yerges; Lambertus Klei; Jane A Cauley; Kathryn Roeder; Candace M Kammerer; Susan P Moffett; Kristine E Ensrud; Cara S Nestlerode; Lynn M Marshall; Andrew R Hoffman; Cora Lewis; Thomas F Lang; Elizabeth Barrett-Connor; Robert E Ferrell; Eric S Orwoll; Joseph M Zmuda
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

10.  Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.

Authors:  Stacy M Plum; Eun J Park; Steve J Strawn; Elizabeth G Moore; Carolyn F Sidor; William E Fogler
Journal:  BMC Musculoskelet Disord       Date:  2009-05-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.